ANI Pharmaceuticals Files 8-K on Financials

Ticker: ANIP · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1023024

Ani Pharmaceuticals Inc 8-K Filing Summary
FieldDetail
CompanyAni Pharmaceuticals Inc (ANIP)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: financial-results, 8-K, regulation-fd

TL;DR

ANI Pharma dropped an 8-K detailing financials - check it for the latest numbers.

AI Summary

ANI Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company, formerly known as BIOSANTE PHARMACEUTICALS INC and BEN ABRAHAM TECHNOLOGIES INC, is incorporated in Delaware and headquartered in Baudette, Minnesota.

Why It Matters

This 8-K filing provides crucial updates on ANI Pharmaceuticals' financial performance and operational status, which is essential for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This filing is a standard 8-K reporting financial results and does not indicate any unusual or significant negative events.

Key Players & Entities

  • ANI PHARMACEUTICALS, INC. (company) — Registrant
  • January 13, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 58-2301143 (tax_id) — I.R.S. Employer Identification No.
  • 210 Main Street West Baudette, Minnesota 56623 (address) — Principal executive offices
  • ( 218 ) 634-3500 (phone_number) — Registrant's telephone number
  • BIOSANTE PHARMACEUTICALS INC (company) — Former company name
  • BEN ABRAHAM TECHNOLOGIES INC (company) — Former company name

FAQ

What specific financial results are being reported in this 8-K?

The filing indicates it pertains to 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.

What is the primary purpose of this 8-K filing?

The primary purpose is to report on the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported is January 13, 2025, which is also the date of the report.

What were ANI Pharmaceuticals' former company names?

ANI Pharmaceuticals was formerly known as BIOSANTE PHARMACEUTICALS INC and BEN ABRAHAM TECHNOLOGIES INC.

Where is ANI Pharmaceuticals, Inc. headquartered?

ANI Pharmaceuticals, Inc. is headquartered at 210 Main Street West, Baudette, Minnesota 56623.

Filing Stats: 594 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-01-13 07:00:28

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On January 13, 2025, ANI Pharmaceuticals, Inc. (the "Company") issued a press release announcing select preliminary unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024, as well as preliminary 2025 financial guidance. A copy of the press release is furnished herewith as Exhibit 99.1.* In addition, on January 14 2025, Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, Inc., will present at the 2025 J.P. Morgan Healthcare Conference in San Francisco, California. A copy of the investor presentation is attached as Exhibit 99.2 hereto and incorporated herein by reference.*

01

Item 7.01 Regulation FD Disclosure The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*

01 Exhibits

Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated January 13, 2025 99.2 Investor Presentation, dated January 14, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 13, 2025 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.